May 10, 2024

Costs, enrollments higher than expected in first monthly Medicaid financial report

Article origination IPB News
The first report provides data on Medicaid enrollment, expenditures and funding as of February 2024. - Lauren Chapman / IPB News

The first report provides data on Medicaid enrollment, expenditures and funding as of February 2024.

Lauren Chapman / IPB News

The Family and Social Services Administration said Medicaid spending is more than $100 million above forecast in its first monthly financial report.

In January, FSSA announced it would improve its forecasting and budget monitoring processes to address transparency concerns following the state’s $1 billion Medicaid shortfall. The first report provides data on Medicaid enrollment, expenditures and funding as of February 2024.

The report shows Medicaid enrollments are about 1 percent higher than expected. FSSA said it anticipated more disenrollments between January and March 2024, but that has not happened. It also said the implementation of continuous eligibility requirements for children is also driving the increased year-over-year enrollment.
 


 

Medicaid costs are nearly 1 percent over the forecasted amount. The agency said the expenditures are driven by Home and Community Based Services expenditures and rate investments for providers.

The report also said Medicaid funding was about $22 million below the forecast.

FSSA said financial reports will be updated “approximately” once a month, but noted data is subject to revisions and modifications to account for the “most up-to-date data.”

Abigail is our health reporter. Contact them at aruhman@wboi.org.

Copyright 2024 IPB News.

 

Support independent journalism today. You rely on WFYI to stay informed, and we depend on you to make our work possible. Donate to power our nonprofit reporting today. Give now.

 

Related News

Is there an outbreak of Lyme disease this year? No, but tick diseases are on the rise.
How supporting caregivers could make a difference in dementia
FDA approves a second Alzheimer's drug that can modestly slow disease